Compare NABL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | SDGR |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.6M | 925.8M |
| IPO Year | 2021 | 2020 |
| Metric | NABL | SDGR |
|---|---|---|
| Price | $3.64 | $13.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $8.31 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $511,430,000.00 | $255,869,000.00 |
| Revenue This Year | $11.04 | $0.76 |
| Revenue Next Year | $8.53 | $4.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.71 | ★ 23.29 |
| 52 Week Low | $3.24 | $10.95 |
| 52 Week High | $9.04 | $27.63 |
| Indicator | NABL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 61.15 |
| Support Level | $3.24 | $11.18 |
| Resistance Level | $5.22 | $13.36 |
| Average True Range (ATR) | 0.35 | 0.66 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 18.04 | 85.17 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.